| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765167 | AQUESTIVE | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(4 months from now) | |
| US8603514 | AQUESTIVE | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(6 months from now) | |
Sympazan is owned by Aquestive.
Sympazan contains Clobazam.
Sympazan has a total of 2 drug patents out of which 0 drug patents have expired.
Sympazan was authorised for market use on 01 November, 2018.
Sympazan is available in film;oral dosage forms.
The generics of Sympazan are possible to be released after 03 April, 2024.
Drugs and Companies using CLOBAZAM ingredient
Market Authorisation Date: 01 November, 2018
Treatment: NA
Dosage: FILM;ORAL
SYMPAZAN family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11541002 | OTTER PHARMS | NA |
Jan, 2040
(16 years from now) | |
Sympazan is owned by Otter Pharms.
Sympazan contains Clobazam.
Sympazan has a total of 1 drug patent out of which 0 drug patents have expired.
Sympazan was authorised for market use on 01 November, 2018.
Sympazan is available in film;oral dosage forms.
Sympazan can be used as method of treating seizures.
The generics of Sympazan are possible to be released after 31 January, 2040.
Drugs and Companies using CLOBAZAM ingredient
Market Authorisation Date: 01 November, 2018
Treatment: Method of treating seizures
Dosage: FILM;ORAL
SYMPAZAN family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic